• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

CareDx to Acquire Naveris for $160M to Expand into HPV-Driven Cancer MRD Monitoring

by Fred Pennic 04/29/2026 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
CareDx to Acquire Naveris for $160M to Expand into HPV-Driven Cancer MRD Monitoring

What You Should Know

  • CareDx has entered into a definitive agreement to acquire Naveris, a precision oncology company specializing in blood-based monitoring for viral-mediated cancers.
  • The deal includes $160M in up-front cash, with potential for an additional $100M based on future revenue milestones.
  • Naveris’ flagship platform utilizes Tumor Tissue Modified Viral (TTMV®) DNA to detect and monitor HPV-driven cancers with high accuracy.
  • The acquisition is expected to close in the third quarter of 2026, subject to customary closing conditions.
  • Naveris reported unaudited revenue of $34M in 2025, with a projected annual growth rate of 30-40% over the next three years.

CareDx, traditionally a leader in the transplant diagnostics space, has made a significant move to diversify its portfolio by acquiring Naveris, a commercial-stage precision oncology firm. This $260 million deal marks a major expansion of CareDx’s U.S. Precision Medicine Testing Services, moving beyond organ health into the high-growth field of liquid biopsy for cancer surveillance.

The acquisition centers on Naveris’ proprietary NavDx® test, a clinically validated liquid biopsy that measures fragments of viral DNA released from tumor tissue. This “tumor-naïve” approach is particularly effective for human papillomavirus (HPV)-driven cancers, providing a non-invasive way to manage patients from initial diagnosis through post-treatment molecular residual disease (MRD) surveillance.

Leveraging Core Competencies in Specialty Markets

The acquisition of Naveris will enable CareDx to target concentrated specialty markets characterized by a high burden of disease and a requirement for repeat testing. This aligns with CareDx’s existing expertise in navigating complex clinical workflows and generating the evidence necessary for robust insurance coverage and reimbursement.

Naveris has already seen strong commercial traction, having performed over 130,000 tests to date. Its solutions are already leading the market in Head & Neck and Anal cancer MRD surveillance. John Hanna, President & CEO of CareDx, noted that the acquisition allows the company to apply its strengths in building belief in molecular testing to a technology that is still in the early stages of broad clinical adoption.

Financial Performance and Strategic Outlook

Financially, the deal adds a rapidly growing revenue stream to CareDx’s balance sheet. Naveris’ performance in the first quarter of 2026 showed approximately $12 million in revenue with strong gross margins of 65%. Despite a small net operating loss in Q1, CareDx expects the transaction will not impact its 2026 AEBITDA guidance.

The integration of Naveris’ 100 employees and its accredited high-complexity laboratories in Massachusetts and North Carolina will provide CareDx with the operational infrastructure to scale these oncology services nationwide. As the two companies combine forces, the focus will remain on improving patient outcomes by delivering disruptive technology that simplifies how viral-driven cancers are detected and managed.

Why This Matters

As HPV-mediated cancers continue to increase in incidence, the ability to detect recurrence earlier and more accurately than conventional imaging will become the standard of care. CareDx isn’t just buying a test; it’s buying a dominant position in the next generation of cancer survivorship.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Healthcare Mergers & Acquisitions, Oncology Platform

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |